[US Stock Market Fluctuation] Nektar Therapeutics plunged on October 1: positive news priced in and uncertainty over litigation compensation

Nektar Therapeutics October 1 Major Decline Interpretation

Key words: Positive news realized, litigation compensation uncertainty

1. On September 24, 2026, a jury ordered Eli Lilly to pay Nektar Therapeutics $90 million plus interest, but the judgment still requires further proceedings and may be appealed. The compensation is less than the approximately $1 billion previously sought by the company, and the actual amount received remains uncertain.

2. From September 30 to October 1, 2026, the company announced positive clinical data for Rezpegaldesleukin and disclosed the initiation of a third Phase III trial. After these catalysts materialized, there was a lack of unexpectedly positive new information in the short term, leading to sell pressure as good news was already priced in.

3. As of August 14, 2026, the company remains in the clinical stage, with its core product yet to be commercialized. The business depends on the progress of Rezpegaldesleukin, and ongoing R&D investment as well as subsequent financing may bring operational and equity dilution risks.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)